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brochures to access a web-based survey (May 5-July 18, 2014) of demographic & 
disease characteristics, respondents’ lifestyle & health ratings, and their percep-
tion of IV infusions before and after initiating therapy. The analysis was exploratory 
and descriptive; data collected was a self-reported ordinal (scale, low-high, 1-10) 
with medians (IQR) reported. A stepwise (backward) multinomial logistic regres-
sion was conducted to determine predictors of a positive perception of IV infu-
sions. RESULTS: There were 1,762 respondents from 10,000 distributed brochures 
(18%). The majority of patients were: bio-naïve, employed, busy/active, and treated 
for inflammatory bowel disease. Median current health rating was high 8(6-9). The 
perception of IV infusions improved from initial treatment; majority of patients 
rated it as 5/10 prior to starting therapy vs. 8/10 after multiple infusions (p< 0.0001). 
Predictors of a positive IV experience were ‘satisfaction with the PSP coordina-
tor’ (OR= 3.0, 95% CI= 1.5-5.7) and ‘receiving an accurate description of treatment 
through the PSP from a physician’ (OR= 3.6, 95%CI= 2.2-5.9). CONCLUSIONS: 
Although there is selection bias, we found that patients have a positive experience 
with the PSP and report significant improvements in their perception of IV infusion. 
Regression analysis suggests that providing patients with an accurate description of 
the treatment at the PSP can improve the perception of the IV experience.
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OBJECTIVES: Intravenous infusions (IV) vs. subcutaneous injection (SQ) biologic 
products offer advantages and disadvantages to patients with inflammatory bowel 
disease (IBD). This study examines potential predictors of IV vs. SQ openness/pref-
erence among patients with IBD. METHODS: Patients (n= 263) completed a self-
administered, web-based questionnaire assessing demographics, health, disease, 
treatment characteristics, behaviors, and attitudes. Patients included: U.S. adults 
(aged ≥ 18) diagnosed with ulcerative colitis (UC; n= 140), Crohn’s disease (CD; n= 123), 
receiving immunomodulator treatment, but biologics-naïve. Chi square and t tests 
compared patients open vs. not open or preferring vs. not preferring IV. Logistic 
regression models predicted openness and preference as a function of potential pre-
dictors. RESULTS: Among all patients (mean age= 45.8, 57.1% female, 23.5% minority, 
and mean years since diagnosis= 10.7), 74.2% were open to starting biologics after 
discussion with their physicians, 64.6% (n= 170) were open to IV, and among those, 
34.7% (n= 59) preferred IV vs. SQ. Potential predictors of openness to IV included: 
considering one’s physician’s advice to be very-to-extremely influential for treat-
ment decisions (OR= 4.67; 1.87-11.64), male vs. female (OR= 2.94; 1.41-6.10), number 
of emergency room, hospital, and/or physician visits for UC/CD in the past 6 months 
(OR= 1.24; 1.07-1.43), ever experiencing fever as UC/CD sign/symptom (OR= 2.81; 1.21-
6.52), and awareness of infusion for UC/CD (OR= 2.38; 1.10-5.16); intention to delay 
biologics treatment due to safety perceptions inhibited openness to IV (odds ratio 
[OR]= 0.48; 95% confidence interval [CI]: 0.35-0.66); all p< .03. Potential predictors 
of preference for IV over SQ included: higher relative openness to office/hospital/
medical facility vs. home site of care (OR= 5.72: 3.51-9.31), receiving/ever having 
received infusion (OR= 4.11; 1.31-12.95), and detailed discussion of redness/swelling 
after injection (OR= 4.15; 1.29-13.39), all p< .02. CONCLUSIONS: The current study 
helps inform patient characteristics, attitudes, and disease and treatment history 
indicating interest in IV biologics treatment, which can help enable shared decisions 
to best benefit patients with IBD.
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OBJECTIVES: To investigate the relationship between patient-reported outcomes 
and durability of response using data from a phase 2 study of single-agent ibrutinib 
for patients with previously-treated MCL. METHODS: The phase 2 SPARK study 
evaluated the efficacy and safety of single-agent ibrutinib in patients with MCL who 
had received a rituximab-containing regimen and had progressed after ≥ 2 cycles of 
bortezomib therapy. In this multicenter, single-arm study, patients were enrolled to 
receive 560 mg/day ibrutinib continuously until progressive disease (PD) or unac-
ceptable toxicity. The primary end point was the overall response rate in response-
evaluable patients, as assessed by an Independent Review Committee. Secondary 
end points included patient-reported outcomes (FACT-Lym). RESULTS: Overall, 25 
of 110 evaluable patients (22.7%) were considered to have primary resistant disease 
(PD at first disease evaluation), with 85 of 110 (77.3%) considered as “responders”: 
22 patients (20%) were considered to have moderate response (stable disease [SD] 
or better, but with PD within 12 months; MR group), and 63 patients (57.3%) were 
considered to have durable response (SD or better, maintained for > 12 months; 
DR group). Median progression-free survival for the total evaluable population 
was 10.5 months; 4.1 months for the MR group and 16.8 months for the DR group. 
Additionally, 67 of 109 response-evaluable patients who had PRO results (61.5%) 
achieved a clinically-meaningful improvement in lymphoma symptoms based on 
EORTC QLQ-C30 cancer mapping algorithms ranged from 0.70 to 0.92. Utility values 
derived from the two versions of the MF-8D were also within this range, at 0.79 
(equal weighting) and 0.73 (Rasch weighting). Clinical opinion indicated that the 
MF-8D captures the key symptoms of PV (e.g., pruritus, abdominal pain/discomfort, 
bone pain, night sweats) better than the other cancer algorithms. CONCLUSIONS: 
The MF-8D may be more appropriate than other cancer algorithms for estimating 
utility values for PV patients, as it includes the most important symptoms of PV. 
This measure is expected to better capture treatment-specific differences affect-
ing HRQoL that are important for the economic evaluation of emerging therapies.
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OBJECTIVES: Hereditary haemochromatosis (HH) is a common autosomal reces-
sive disorder amongst persons of European heritage. Elevated hepcidin production 
increases the absorption of dietary iron, which is stored in the parenchymal tissues 
of the heart, liver and pancreas. Treatment consists of regular venepuncture, and if 
implemented early, prevents organ damage. If untreated, iron overload can be a cause 
of morbidity and mortality. To date, a lack of robust health economic evidence has 
been cited as one of the barriers to establishing screening programs for HH. Previous 
analyses have used unvalidated estimates of health state utility values (HSUV). This 
is in part due to no published estimates of HSUV. This study sought to estimate HSUV 
directly from people with different levels of severity of HH of in Australia. METHODS: 
Volunteers with HH were recruited to complete a web-based survey as part of a 
national cost of illness study for HH. HSUV was estimated using the Assessment of 
Quality of Life 4D (AQOL-4D) instrument. Severity of HH was categorised according 
to the method recommended by the European Association of the Study of the Liver. 
Multivariate regression analysis was performed to identify parameters associated 
with HSUV. RESULTS: Between November 2013 and November 2014, 221 people com-
pleted the survey. Increasing severity of HH was negatively associated with HSUV. 
Mean (standard deviation) HSUV were 0.76 (0.21), 0.81 (0.18), 0.60 (0.27), and 0.50 (0.27) 
for grades 1-4 HH respectively. CONCLUSIONS: Increasing severity of HH is associated 
with decreasing HSUV. Previous cost utility analyses have used higher HSUV which 
likely resulted in underestimates of the cost effectiveness of screening programs 
for HH. The HSUV reported in this paper are the most robust available and their use 
would improve the validity of future economic models for HH.
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OBJECTIVES: To assess the health status of haemophilia B patients treated with 
nonacog beta pegol, a novel recombinant Factor IX (FIX) product with prolonged 
half-life and less frequent dosing requirements. METHODS: Severe/moderate hae-
mophilia B (FIX activity level ≤ 2%) is an inherited bleeding disorder characterised 
by recurrent, often spontaneous bleeding episodes, in particular musculoskeletal 
bleeds. Modern management includes self-infusion of FIX 2-3 times/week to prevent 
bleeds (prophylaxis) or on-demand treatment (OnD). Haemophilia B patients aged 
13-70 years were included in a single-blind phase 3 trial evaluating safety and effi-
cacy of nonacog beta pegol. Patients were treated OnD for 28 weeks, or randomised 
to once weekly prophylaxis with 10 or 40 IU/kg for 52 weeks. All patients completed 
the 3 level EuroQol-5 dimensions (EQ-5D-3L) at baseline and end-of-trial. EQ-5D VAS 
ranges from 0-100. Higher score represents better health status. Changes in scores 
were compared to no change using the Wilcoxon signed rank test. RESULTS: 74 
patients were included in the Full Analysis Set (15 OnD; 30 on prophylaxis with 10 
IU/kg dose and 29 on prophylaxis with 40 IU/kg). 56 patients were 18-70 years and 18 
were 13-17 years. A significant improvement in EQ-5D index score was observed in 
the overall set (mean change = 0.04, p= 0.016), but no significant change was observed 
for the different dose groups. In subset analysis of the high dose prophylaxis arm, 
mean EQ-5D VAS was 74.3±18.0 at baseline and 83.9±14.5 at end-of-trial, leading to 
a statistically significant improved mean change in score (p= 0.030). The change was 
non-significant in the OnD and low dose prophylaxis arms. CONCLUSIONS: In a 
phase 3 clinical trial, haemophilia B patients treated with the long-acting FIX nona-
cog beta pegol showed a significant improvement in their health status. Patients 
treated with the prophylaxis dose of 40 IU/kg/weekly demonstrated significant 
improvement in health status according to the EQ-5D VAS.
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OBJECTIVES: Patients with auto-immune diseases who are treated with infliximab 
(IFX) intravenous (IV) infusions are managed through a manufacturer-sponsored 
patient support program (PSP). Previous studies have had conflicting conclusions 
regarding patient preferences of modes of administration of biologics, with impli-
cations of negative perceptions of IV infusions. The aim of this study was to assess 
patients’ experience of IFX IV therapy administered in the PSP and to determine 
predictors of a positive perception of IV infusions. METHODS: In this nationwide, 
cross-sectional survey, patients currently receiving IFX within the PSP were given 
